"I think it would be better for those of us who have the disease not to be ashamed". Insights from people living with chronic hepatitis B virus infection and healthcare workers providing HBV care in Kilifi, Kenya.

Short title: Insights on HBV care in Kilifi, Kenya

Louise O Downs[1,2], Juliet Odhiambo[2], Mwanakombo Zaharani[2], Oscar Chirro[2], Benson Safari[2], Janet Seeley[3,4], Philippa C Matthews [5,6,7], Nadia Aliyan[8] and Nancy Kagwanja[2].

1. Nuffield Department of Medicine, University of Oxford, UK
2. KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
3. London School of Hygiene and Tropical Medicine, Keppel St, London, WC1E 7HT, UK
4. Africa Health Research Institute, KwaZulu-Natal, South Africa
5. The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
6. Division of Infection and Immunity, University College London, London, UK
7. University College London Hospital, 235 Euston Road, London NW1 2BU, UK
8. Kilifi County Hospital, Kilifi, Kenya

Corresponding author: Louise Downs. Louise.downs@exeter.ox.ac.uk

Keywords: Hepatitis B virus; Patient voice; Lived experience; Barriers to care; Care cascade; Africa; Kenya; Peer support; Education; Decentralisation; Treatment; Stigma.

Author Contributions

Study conceptualisation and design: LD, JO, MZ, OC, BS, PM

Data curation: LD, JP, MZ, OC, BS, NA, NK

Data analysis: LO, PM, JS, NK

Supervision: JS, PM, NA, NK

Writing – original draft and preparation: LD

Writing – Review and editing: JS, JO, PM, NA, NK

Abstract

Chronic hepatitis B infection (CHB) causes over 1 million deaths annually, with a large burden of morbidity and mortality in the WHO-African Region (WHO-AFRO) where <5% of people are diagnosed and 0.2% are on treatment. Studies have shown that understanding of hepatitis B virus (HBV) here is often poor, and people living with HBV (PLWHB) can experience stigma and discrimination. However there has been little documentation on the impact of an HBV diagnosis on the lives of PLWHB in the WHO-AFRO region or community involvement in improving care provision. We undertook two focus group discussions (FGDs) with PLWHB and two with healthcare workers (HCWs) providing HBV care at Kilifi County Referral Hospital (KCRH), Kenya to explore experiences of living with HBV and barriers to accessing care. FGDs were conducted primarily in Kiswahili, transcribed verbatim and translated into English. The data were analysed thematically using NVivo version 14.

PLWHB and HCWs at KCRH had a good understanding of HBV which was likely influenced by a concurrent research study on HBV, however they reported low awareness in the general community, and there is no local name for the infection. Many PLWHB were shocked at their initial diagnosis with mixed reactions from friends and family. Costs of transport and concerns about lost employment were the biggest barriers to care. Many people suggested decentralised clinics would reduce loss to follow up, however others would rather be treated far from home to preserve anonymity. Stigma was highlighted as a major issue, leading to feelings of isolation, rejected and discrimination. Community education, wider testing and advocacy by well-respected community members were mentioned as key methods to reduce HBV transmission. Decentralisation of clinics may improve

access to care; however, this needs to be developed in careful consultation with PLWHB to ensure they are acceptable and accessible to all.

Introduction

Approximately 256 million people worldwide are living with chronic hepatitis B infection (HBV) with the highest burden of infection being in the WHO-African Region (WHO-AFRO) (1). HBV has, however, been neglected in terms of healthcare provision, education, research and policy (2,3). An estimated 4.2% of people living with HBV (PLWHB) in WHO-AFRO are diagnosed, and knowledge around HBV both in communities and healthcare facilities is often limited (1,4). In Kenya, an estimated 3-5% of the population is living with HBV (5), but screening is largely restricted to those living with HIV, blood donors, dialysis patients and in some locations antenatal screening. There is minimal population screening and little vaccination outside of the childhood immunisation series. Elimination efforts in Kenya are gaining traction with the Ministry of Health working on new HBV management guidelines and a National Strategic Plan; the community voice along with challenges faced by healthcare workers (HCWs) in caring for PLWHB must be considered in these efforts.

Throughout the WHO-AFRO region, reports are emerging of the impact of an HBV diagnosis on those living with the infection, and a new HBV stigma survey has been piloted in selected countries by the World Hepatitis Alliance (6). It is widely agreed that representation of those with lived experience is urgently needed to improve representation and advocacy, and inform improved service provision, which in turn will drive progress towards global elimination targets (7). The positive role of peer support workers in HBV care is being increasingly recognised, to encourage testing, improve treatment adherence and reduce stigma (8). Along with this, healthcare workers (HCWs) providing care for PLWHB have a unique insight into issues including misinformation, stigma and barriers to long-term follow-up and medication. They also understand the current healthcare infrastructure for PLWHB, have insights into gaps and challenges, and can advise how access could be improved.

We set out to engage people living with HBV, and HCWs caring for PLWHB in Kilifi County Referral Hospital (KCRH), Kenya, to generate evidence to inform care delivery, by establishing a platform for scale up of qualitative data collection in this setting and elsewhere. We convened focus group discussions (FGDs), aiming to i) explore understanding of HBV infection on an individual and community level, ii) discuss how the lives of PLWHB have changed since their diagnosis and iii) investigate barriers to receiving care and consider how these could be reduced. The methods and results of this study are reported in compliance with the Standards for Reporting Qualitative Research (SRQR)(9).

Materials and methods

i) Study context

We conducted FGDs with both PLWHB and HCWs providing HBV services. This study was conducted at Kilifi County Referral Hospital (KCRH), a referral facility in Coastal Kenya, servicing an area of around 12 000 km^2 and a population of 1.5 million people. KCRH has 300 inpatient beds and sees 193 000 outpatients every year. Table 1 summarises the distribution of health facilities in Kilifi County (10). Poverty levels in Kilifi are above the national average for Kenya, with 53% of the population living in poverty in 2022 compared to the national average of 40% (11). At the time of this study, HBV care at KCRH was provided at the Comprehensive Care Clinic (CCC), which is a secondary care outpatient clinic primarily designed for people living with HIV. The CCC provides adherence counselling, medication and follow up for both adults and children living with HBV. At KCRH, there is no routine mechanism for offering further laboratory or imaging assessment to determine HBV treatment eligibility, therefore standard care is that all those testing HBsAg positive receive nucleoside analogue (NA) therapy using tenofovir/lamivudine (TDF/3TC) combination therapy. This approach is in line with conditional recommendations for 'treat all' which are incorporated in new WHO guidelines released in 2024 (12).

Health Facility Type	Number in Kilifi County
Dispensary	132
Health Centre	18
Public Hospitals	
County Referral Hospital	1
Sub-County Hospital	8
Faith Based Facilities	25
Private, for-profit health facilities	186

Table 1: The distribution of health facilities in Kilifi County, Kenya (10).

ii) Data collection

We conducted four FGDs, two with PLWHB (consisting of six men and seven women) on 18th June 2024, and two with HCWs (consisting of seven men and seven women) on 14th November 2024. PLWHB were invited to participate in FGDs during peer support educational sessions initiated by the CCC matron when coming to pick up medication, and HCWs were invited via a group messaging platform for CCC staff. Participants were purposively sampled to create groups with diverse ages and experience, and in the case of HCWs to ensure a spread of cadres involved in HBV service delivery.

FGDs were held in private rooms in the CCC to promote participant privacy. Participants were given a number from 1-6 or 1-7 within their group to enhance anonymity of the respondents. FGDs with PLWHB were conducted primarily in Kiswahili by MZ, OC, and BS and facilitated by JO, a member of the Community Liaison Group from KEMRI Wellcome Trust Research Programme experienced in qualitative data collection. FGDs with HCWs were conducted in both English and Kiswahili by MZ and JO, facilitated by LD. Topic guides were used to direct FGDs, informed by study objectives and literature about patient experiences of accessing and receiving HBV care. The topic guides covered the understanding of HBV, reactions to diagnosis, the impact on the lives of PLWHB, barriers to care and how these could be reduced (13). FGDs took around 1.5 hours each, were audio recorded using an encrypted dictation device from KWTRP, and those participating were given refreshments. PLWHB

127 attending specifically for the FGDs were compensated lost earnings of around USD $5, as is standard
128 for community engagement activities at KWTRP.
129
130 ***iii) STRIKE-HBV partner study***
131 This work was undertaken in collaboration with the STRIKE-HBV study, a research study funded by
132 the Wellcome Trust, based at KEMRI-Wellcome Trust Research Programme (KWTRP). STRIKE-HBV
133 offered free HBV testing to all those attending KCRH between March 2023 – May 2024, and free liver
134 health assessment to anyone living with HBV as previously described (14). STRIKE-HBV enrolled 102
135 PLWHB, including those newly diagnosed and those already known to be living with HBV and
136 engaged in care. Activities undertaken by STRIKE-HBV including the status of HBV care in KCRH are
137 detailed in table 2 and educational material developed for STRIKE-HBV is available online (15). All
138 PLWHB who took part in these FGDs were also enrolled in STRIKE-HBV.
139

Category	Prior to STRIKE-HBV	Interventions undertaken by STRIKE-HBV	Situation after STRIKE-HBV
HBV education for staff	None provided. Patients managed in the CCC with no staff training.	Hospital education sessions as part of continuing medical education (CME) and to individual departments, particularly the CCC.	Staff have continued HBV education including reaching out with questions. KCRH is developing hospital specific guidelines for HBV management.
HBV community education	None provided.	- Health talks in Kiswahili detailing HBV symptoms and transmission 3 x week in KCRH OPD. - Information leaflets provided (15) - Education for PLWHB combined with peer support sessions at the CCC.	Staff able to provide improved education to PLWHB and antenatal women regarding HBV testing.
HBV testing	No routine HBV testing either free of charge or paid. No advocacy for testing.	Provision of free HBV testing for non-pregnant adults from March 2023 – June 2024.	HBV testing promoted and offered to antenatal women (although currently at an individual cost)
Peer Support	No peer support for HBV	Nil specific implemented by STRIKE-HBV, but study staff facilitated peer support sessions initiated by the CCC by providing education.	CCC began peer support sessions for PLWHB during STRIKE-HBV and these are continuing following study completion.

140
141 **Table 2:** Detailing i) Care for people living with HBV (PLWHB) at Kilifi County Referral Hospital (KCRH) prior to
142 the STRIKE-HBV study; ii) Interventions undertaken by the STRIKE-HBV study and iii) Changes in care for PLWHB
143 after STRIKE-HBV completion. Information leaflets were developed in collaboration with the Hepatitis B

Foundation (16). CME sessions mostly targeted doctors, nurses, pharmacists and students. OPD – outpatients department; CCC – comprehensive care clinic.

iv) Data Analysis

Following FGDs, audio files were transcribed verbatim and translated into English and analysed in Nvivo version 14. Both inductive and deductive thematic analysis (17) was used to scrutinise the data to identify and analyse patterns and draw out themes using constant comparison technique (18). Transcripts from all FGDs were examined on a line-by-line basis and the coding framework was first developed by LD and refined on discussion with the research team. Codes were developed based on the original questions asked by the interviewers and areas of interest to the authors, along with new themes being identified 'a priori' based on existing literature and tailored to the local context (4,19).

v) Ethics and governance

This study was approved by the Scientific Ethics Review Unit (SERU) (SERU 3416). Written consent was obtained from all FGD participants prior to participation in FGDs, including consent for audio recording.

Results

Focus groups with PLWHB included six men and seven women with a median age of 37 years (range 24 – 61). Five participants had been newly diagnosed with HBV in the STRIKE-HBV study, eight already knew their diagnosis prior to enrolment in STRIKE-HBV. Two of those participants who were newly diagnosed had family members already known to be living with HBV.

HCW focus groups consisted of nine women and five men, with a median age of 31 years (range 18 – 61). The range of cadres included three clinical officers, three community health promotors (CHPs), two nurses and then one of each: counsellor, adherence supervisor, peer educator, nutritionist, records officer, and laboratory technician.

171 ***i) Knowledge and understanding of HBV***

172 Both PLWHB and HCWs knew that HBV is a virus causing liver disease and is transmitted sexually or
173 by contact with infected blood. Sexual transmission was mentioned most by both groups, including
174 men and women, and still considered the most common route of transmission, especially by PLWHB,
175 although other routes were mentioned. As participating PLWHB were those already receiving
176 treatment, they were aware of HBV medication, and some HCWs specifically mentioned the use of
177 tenofovir/lamivudine combination therapy. In both groups however, there was still some confusion
178 around what happens after taking treatment for 6 months - some PLWHB thought they would be
179 cured; however others knew this was not the case:

180

181 *"In addition, if you have liver disease, you can, if you use the medicine properly for six months*
182 *and if you are tested, it may be that the virus is gone", (participant 5, PLWHB, male, FGD 1).*

183

184 Within the HCW groups, although there was discussion around poor community HBV knowledge,
185 they also noted a significant knowledge gap amongst HCWs prior to the STRIKE-HBV study. They felt
186 STRIKE-HBV had given them confidence in HBV management, and that many healthcare providers in
187 other facilities were still providing incorrect information:

188

189 *"At first, I didn't know how to give the treatment. I used to just guess. I didn't know how long I*
190 *should be giving this medication. I didn't even have the knowledge of package information to*
191 *give the patient but right now I can stand comfortably with confidence and tell the patient what*
192 *he or she is going to take and for how long the treatment should be and what he or she should*
193 *do." (participant 7, HCW, male, FGD 2)*

194

195 When discussing a local language description of HBV, participants from both groups stated it was an
196 unknown disease, or only described by the symptoms:

197 *"But this hepatitis B virus is unknown, let's say it has no name. People don't know, they only know*
198 *AIDS", (participant 1, PLWHB, female, FGD 2).*
199
200 *"In Kilifi they just describe the complications, when you have jaundice they say "yellow", when*
201 *you have ascites they say "mwamimba" [pregnancy], only that." (participant 1, HCW, female,*
202 *FGD 2)*
203
204 Others reported HBV infection was called *'cancer'*. Several people mentioned that they had heard of
205 HBV as it was causing illness in their village, and perceived it to be a death sentence:
206
207 *"I knew it [HBV] was killing people in the village. You don't know if he is starting [to get unwell]*
208 *but you will only know that something has reached. That is, they don't get medicine, that is, there*
209 *is no nursing, it is only when he is taken to the hospital, when he begins to be treated, then death*
210 *has already arrived" (participant 6, PLWHB, male, FGD 1).*
211
212 Several respondents in both HCW and PLWHB groups mentioned that PLWHB were sometimes
213 thought to be bewitched, and they would go to traditional healers to be cleansed and take herbal
214 medications instead of tenofovir, or to church to pray to be cured:
215
216 *"…those [with HBV] who have complications, or have ascites, in local language or native*
217 *language we call it "mwamimba" [pregnant] and so they say that they have been bewitched and*
218 *somebody has thrown something in their stomach and now like you are like a man but you are*
219 *"pregnant". (participant 5, HCW, female, FGD 2).*
220
221 ***ii) Comparison with HIV***

222 Both PLWHB and HCWs discussed the confusion between HBV and HIV, particularly given that care is
223 received in the same clinic, and the medication is the same. Many PLWHB found it difficult to accept
224 they did not have HIV, and friends and family sometimes accused them of lying. This was common to
225 both men and women. Many PLWHB felt they needed to 'prove' they didn't have HIV by going with
226 family or partners to be tested:
227
228 *"…one day my wife came and explained to me, "I heard some people say that you have AIDS." I*
229 *told her, "No, I don't have AIDS and if you want to know, let's go, let's all go and be tested"*
230 *(participant 5, PLWHB, male, FGD 2).*
231
232 *"… [many] people who don't understand and then once they get the results and then they are*
233 *being escorted to this building CCC, majority don't get to understand clearly the relationship like*
234 *we are telling them it's not HIV and we are giving them ARV's (anti-retroviral therapy)."*
235 *(participant 1, HCW, female, FGD 2).*
236
237 Several times it was mentioned that HIV was better funded than HBV, and there was not the same
238 level of resources for the two infections.
239
240 ***iii) How lives have changed since HBV diagnosis***
241 We initially discussed reactions to diagnosis, both individually and those of friends and family. Many
242 PLWHB were shocked at their diagnosis and felt anxious as they had little knowledge of HBV. HCWs
243 reported many newly diagnosed people thought they were dying, and associated HBV only with end
244 stage disease. Counselling helped alleviate anxiety and was felt to be very important by both PLWHB
245 and HCWs. Peer support sessions were motivating and HCWs thought these should be given more
246 routinely to allow PLWHB to discuss their concerns. Several PLWHB mentioned that once they got

247 used to their diagnosis, they realised they could continue to take the medication and live just like
248 anyone else.
249
250 Many women diagnosed with HBV had been tested as a condition for travelling abroad for work, and
251 their diagnosis had not been properly explained to them which caused a lot of distress. They felt lost
252 and abandoned, unable to pursue their plans, whilst peers and colleagues went off on their travels.
253
254 *"He [employment agent] refused to tell me because he said [the problem was] either liver or*
255 *kidney. I told him, "Now there is no disease that is good and there is no disease which is bad, you*
256 *can just explain it to me." He said, "Just go to the doctor and get tested or go and get an x-ray*
257 *and he [the other doctor] will explain more, but I won't explain it to you."" (participant 3, PLWHB,*
258 *female, FGD 2).*
259
260 Reactions of friends and family varied. Some were very supportive, went to get tested themselves
261 and encouraged participants to continue medication, but some partners left after the diagnosis.
262 Sometimes after an initial lack of understanding, relatives came to the CCC to seek more information
263 about HBV and its consequences.
264
265 Almost all participants commented that their lives had changed since HBV diagnosis, sometimes in
266 beneficial ways, some less so. One male participant had considerably cut his alcohol consumption
267 due to concerns about his liver:
268
269 *"Even that time I came to be tested, I came already drunk…I have been told "The liver's job is this*
270 *and this and this and when you eat, the food is processed like this and this and this in the*
271 *stomach"… I saw that there is a very important knowledge…. I stopped drinking alcohol; I*

continue to take medicine. So I see there is a big change. That is, since I have been drunk all the time and this time, I can be sober, I'm grateful", (participant 1, PLWHB, male, FGD 1).

Many PLWHB had experienced non-specific symptoms that had improved with treatment such as tiredness, stomach pains and swelling, nausea, itching, heartburn and constipation. Symptom improvement with treatment encouraged them to continue:

"I was given about five days [of medication]. I came back, I came and was given for two weeks, I came back. But since then, I see changes myself even in my body. I don't get hurt a lot and I don't get a lot of fatigue". (participant 7, PLWHB, female, FGD 1).

"I was diagnosed with this disease, and I just saw that I was already dying. But when I got this treatment, I am fine now because even when I was sleeping and I could feel my stomach like water going this way, when I turned over, I could feel like water coming back this way and I said, "My stomach has started to swell too." But this time when I started this treatment, that issue stopped and the anxiety of saying that I was dying because I had not received [education]. This time I have received [education]. Now I know that if I use these drugs properly, I can live normally." (participant 5, PLWHB, male, FGD 1).

Many participants perceived that they had less freedom as they felt they needed to ensure they were home from work at a particular time and sometimes decided not to engage in social activities due to concerns about taking their medication:

"But since I use these drugs, I always tell my friends that I can't walk at night. Because when it reaches eight o'clock, I have to take medicine" (participant 7, PLWHB, female, FGD 1).

298 ***iv) Current provision of HBV care in Kilifi***

299 We discussed with HCWs what care was available for HBV both in KCRH and further afield, and how
300 this had changed since the STRIKE-HBV study. Adherence counselling and medication had always
301 been available at KCRH free of charge for HBV, however as described above, HCWs reported
302 inadequate knowledge about medication and a lack of confidence when prescribing. In Kilifi County,
303 diagnosis was most often made in private facilities prior to travel abroad for work, and treatment
304 was provided primarily at KCRH. Public peripheral facilities and private hospitals often referred
305 patients to KCRH as it was known to have an established hepatitis clinic. Occasionally people would
306 be able to pick up their medication from subcounty hospitals and smaller health centres, but only
307 after education and service establishment by HCWs from KCRH:

308

309 *"So, there were no services [no hepatitis clinic] there, but we had to recreate the services for her*
310 *to get the drugs. So, some have opted to go to a smaller health centre, and some to two sub-*
311 *county hospitals, and so we have some sites which are offering [HBV treatment] but the diagnosis*
312 *was done here." (Participant 7, HCWs, male, Group 2).*

313

314 The HCWs however still perceived that peripheral facilities require more support to increase their
315 confidence in providing HBV care. Many health centres and dispensaries had HBV medication
316 available along with adherence counsellors as they cared for those living with HIV, yet patients who
317 desired to get their treatment from their nearby facilities were sometimes still referred upwards to
318 KCRH:

319

320 *"…as much as they wish to go there, some facilities have limited knowledge on client follow up*
321 *and now it becomes a challenge, but we have clients who would prefer to take medication from a*
322 *nearby facility. I have had two who have been returned [to KCRH from peripheral facilities] for*

323 *further management because the dispensary is not well equipped to manage hepatitis clients."*
324 *(FGD 2, HCWs, female, participant 1).*
325
326 Since STRIKE-HBV, HCWs reported they were able to provide better informed psychosocial support
327 for PLWHB. They also encouraged PLWHB to talk to partners and family about testing to try to reduce
328 stigma. They reported encouraging PLWHB to be ambassadors and educate the community about
329 HBV and some HCWs were sharing their improved HBV knowledge with colleagues in peripheral
330 facilities to support them in providing HBV care.
331
332 ***v) Barriers to HBV care and how these can be reduced***
333 ***a. Economic Factors***
334 Economic factors seemed to be the biggest barrier to receiving care. Firstly, the cost of transport to
335 attend a distant hospital-based clinic was mentioned by both HCWs and PLWHB. To counter this cost,
336 many people felt HBV medication should be available at the local dispensary:
337
338 *"Because the rest of us are far away [from the hospital], but if we find our local dispensaries*
339 *nearby, these local medicines, the way we are known, they are placed there. It will be easy*
340 *even for us because we won't have to pay fare", (participant 2, PLWHB, female, FGD 1).*
341
342 *"…they come from far and first they have the transport issues and secondly they are living in*
343 *abject poverty and so most of them they cannot make it to Kilifi and so at least if we have the*
344 *resources [medication] and we dispense the resources [medication] nearer to them then it*
345 *will be better." (participant 7, HCWs, male, FGD 2).*
346
347 Several PLWHB mentioned the need to plan to make sure they had fare to attend clinic. Along with
348 fare, the timing of clinic appointments had little flexibility, and often the patients experienced long

349 waiting times. This was difficult with employment, with men in particular mentioning they struggled
350 to get days off work leading to lost earnings:
351
352 *"So the challenge always arises because maybe your boss refuses to agree with you, maybe it*
353 *[the clinic return date] can be balanced until you get the chance to come take medicine or a*
354 *meeting like this. You may find that your boss telling you, "Now you might not get paid today,*
355 *or we will remove this day from your rest days, we will cut it there". (Participant 5, PLWHB,*
356 *male, FGD 2).*
357
358 The wish for decentralised clinics however was not universal. Several people in both the patient and
359 HCW groups mentioned that (despite the potential higher cost) some PLWHB would prefer to go to a
360 distant clinic (where they are not known) to reduce stigma, and sometimes asking for money for
361 transport caused problems with questions about where they were going:
362
363 *"…many of them still have stigma so they are thinking like if I am seen there, I will be*
364 *isolated, so many prefer to go to those far away hospitals that no one knows, very few said*
365 *they were referred to go to a nearby hospital." (Participant 4, HCW, female, FGD 1).*
366
367 *"[If I ask a friend]: Help me with 200 shillings ($1.5) so that I can go somewhere and then I*
368 *will give you back." He asks, "Where do you want to go?" What do you want to do with it?"*
369 *Now that's where I see the difficulty." (Participant 5, PLWHB, male, FGD 1).*
370
371 **b. Stigma and lack of education**
372 Stigma was raised as an issue by all focus groups, both men and women, with participants
373 highlighting instances of self-stigma and community stigma. Concerning self-stigma, PLWHB felt they
374 were being talked about, and others were distancing themselves for fear of infection:

375

376 *"And if the food itself I can't eat with them at the same table, it is as if I will infect them, I*

377 *should have my own bowl and sit aside", (participant 3, PLWHB, female, FGD 1).*

378

379 As noted earlier, HIV and HBV services are currently integrated in KCRH and all clients are seen

380 together in the same clinic. PLWHB revealed tensions around this, with some participants feeling

381 they should have a separate clinic from those living with HIV, partly due to stigma when seen

382 entering the HIV clinic, but also due to long wait times when being seen together. Some people felt

383 those living with HIV were prioritised, although there was also agreement that separating those with

384 HBV and HIV could increase stigma, and they should all be together because they had more in

385 common than differences:

386

387 *"I see they should just be together because we cannot separate them [HIV patients]. We all say*

388 *we are birds of the same colour, we are going in the same direction. It means that if we separate*

389 *them, it is like we are bringing that stigma and we don't want it to be like that", (participant 2,*

390 *PLWHB, male, FGD 2).*

391

392 Education was seen by both PLWHB and HCWs as the best way to combat stigma, including

393 continuing education for PLWHB through expert led peer support sessions, along with informing the

394 immediate family and community. Several people mentioned initiatives on television or the radio to

395 spread information about HBV, and respected community members such as pastors and chiefs to

396 encourage testing and treatment. Several people in the HCW group felt the community health

397 promotors (CHPs) could play a pivotal role in HBV sensitisation and treatment adherence. They

398 mentioned how CHPs are funded to visit people living with HIV at home but not those living with

399 HBV:

400

401 *"I feel the CHP should also be brought on board on issues of Hepatitis B sensitisation and*
402 *treatment adherence. Because you will get CHP bringing a referral or a patient who had*
403 *defaulted treatment for [HIV treatment] but they will never do follow up for a client with*
404 *Hepatitis." (Participant 1, HCW, female, FGD 2).*
405
406 ***vi) Reducing transmission***
407 When asking PLWHB how to reduce HBV transmission, practical ways were discussed to reduce
408 contact with the virus including safe sexual practices, and one participant mentioned wearing gloves
409 before helping anyone who was injured. Reducing the sharing of instruments that spread HBV was
410 felt to be important, particularly needles, razors and toothbrushes, and a few participants mentioned
411 vaccination, but did not distinguish groups they felt could benefit from vaccination, or how
412 vaccination should be offered.
413
414 Both PLWHB and HCWs felt that community awareness is paramount in stopping the spread of HBV,
415 including reducing fears of testing by educating people that HBV can be managed well with
416 medication, which is available free of charge, and is not a death sentence. Participants suggested
417 testing could be promoted through TV and radio campaigns, by religious leaders and the Ministry of
418 Health:
419
420 *"So you find when people already know that [HBV can be dangerous], if the pastors also*
421 *intervene, after explaining, now you will get a large group that say, "Uh, let me look at myself."*
422 *And there I think we will find many people will volunteer [for HBV testing]. You can't go to*
423 *someone's house and grab his shirt and bring him here, no, it's up to him to decide and say, "At*
424 *my own free will, let me check.""", (participant 6, PLWHB, male, FGD 2).*
425

426 Access to testing was also mentioned by several PLWHB, ensuring the community knows this is
427 available, where to be tested and ideally testing being offered for free. Many HCWs and PLWHB
428 discussed that HBV testing should be part of the routine screening that everyone has when they go
429 to a hospital, like HIV. There was also discussion of the benefits of antenatal testing for HBV, and how
430 this should be routine:

431 *"… There should be free testing, random or all over, everyone to be reached. I can say here in*
432 *Kilifi, the people of Kilifi are lucky because even I am lucky because of your research and the*
433 *services that are provided here." (participant 3, PLWHB, female, FDG 1).*

434 *"…perhaps if the pregnant mother it is her first time, she must come with her husband so that*
435 *they can be tested for AIDS, and the likes. Now I was thinking it would also be good if this*
436 *hepatitis B was placed in that category, when they come to be tested, if she has come to the*
437 *clinic, being tested for the HIV virus, they should also test the Hepatitis B virus…", (participant 6,*
438 *PLWHB, male, FGD 2)*

439

440 Reducing stigma around an HBV diagnosis was felt to be key in reducing transmission. If those living
441 with HBV felt able to reveal and discuss their diagnosis, they could also be the ones to spread
442 awareness and educate their communities:

443

444 *"I think it would be better for those of us who have the disease to not be ashamed. I explain that*
445 *I was diagnosed with that disease [HBV] and that I use those drugs, I tell the people there to go*
446 *to the hospital, not to wait until the organisation reaches the grassroots, it will be too late",*
447 *(participant 4, PLWHB, male, FGD 2).*

448

449 A common theme that ran through all the discussion questions was lack of education. Improved HBV
450 awareness and knowledge was seen as crucial in all areas including reducing stigma, reducing

Knowledge and understanding	How lives have changed	Current care available	Barriers to care	How to reduce transmission and improve care

transmission, improving testing and diagnoses and improving access to care. Both PLWHB and HCWs highlighted this throughout as paramount to improve the lives of PLWHB in Kenya.

Discussion

We set out to explore the experiences of both PLWHB and HCWs providing HBV care in Kilifi Kenya aiming to understand HBV knowledge, impact of HBV on people's lives and barriers to accessing care. Our findings, summarised in Table 3, add to the limited literature exploring the lives of PLWHB in WHO-AFRO countries. Several studies have evaluated different mechanisms to try and improve HBV care, however very few have included the patient voice, or discussed with HCWs involved with patient care when planning interventions, making this a valuable addition to HBV literature (20,21).

Ongoing confusion about medication duration after the initial 6-month period.	Unable to travel abroad due to HBV diagnosis.	Adherence counselling and psychosocial support provided at KCRH.	Economic factors - Cost of transport - Lack of decentralised clinics - Living in poverty - Loss of work - Difficulties getting time off work to attend	- Education about safe sexual practices. - Reduce sharing of household implements (razors/toothbrushes) - Provision of vaccination including birth dose vaccine.
Poor community knowledge with no local language word for HBV	Reduced alcohol intake and better self-care.	Staff at KCRH educate partners and family.		Community educational campaigns.
HCWs poorly informed prior to STRIKE-HBV and incorrect information still given in other facilities	Less freedom in the evenings to meet friends due to medication timing.	Testing not free of charge outside of STRIKE-HBV.	Stigma and lack of education - Self-stigma and community stigma - Concerns from others about transmission - Unhappy about HIV/HBV service integration due to increased stigma.	TV and radio campaigns, advocacy by prominent society members and the ministry of health.
PLWHB concerns about being 'bewitched' and visiting traditional healers to be 'cured'.	Concerns about dying.	No vaccination provided other than the routine infant schedule.		Better availability of free testing, particularly in antenatal women. Testing available in communities.
Confusion with HIV. Many PLWHB having to 'justify' to relatives they don't have HIV.		Smaller facilities have the correct provisions but feel unable to provide HBV care due to lack of knowledge	Lack of freely available testing and vaccination.	Decentralised clinics for those who want them, and education of more HCWs.
				Specific hepatitis clinics, separate from HIV.

Table 3: Summary of the different themes arising from focus group discussions (FGDs) with people living with hepatitis B virus infection (PLWHB) and healthcare workers (HCWs) caring for PLWHB at Kilifi County Referral Hospital (KCRH) in Kilifi, Kenya. HBV – hepatitis B virus.

Financial barriers have also been highlighted elsewhere (22–24), and can lead to catastrophic costs for individuals and families living with HBV (25). In our study, travel costs to the hospital clinic were seen as most prohibitive, whereas in studies from Burkina Faso and Ghana, costs of tests, monitoring and medications were mentioned more commonly (23,26). This may be because in our study testing and nucleoside analogue therapy were provided free at the point of care in KCRH which is not the case in many other countries. Many studies both from within WHO-AFRO and elsewhere have raised concerns around lost employment (27–29) as in our study, and this was particularly common

473 amongst men. Lack of childcare was mentioned as a significant barrier to care in some studies
474 outside of WHO-AFRO (28). This was not mentioned at all in our study or others from Ghana or
475 Burkina Faso (23,24) possibly due to the different family structures in countries in WHO-AFRO
476 compared to those in the Global North, with less reliance on parents being the sole care givers.
477
478 The concerns raised by our participants around the integration of HBV and HIV care particularly
479 related to increased stigma has been discussed previously (30). The utilisation of existing HIV services
480 is one of the key components hypothesised to enable decentralisation of HBV care. However, we
481 suggest that caution is needed, and extensive community education and sensitisation should be
482 done before this is implemented. We also found that there is often confusion between HIV and HBV,
483 which was also the case in Burkina Faso where HBV was closely associated with HIV when explained
484 to patients (23). Although this was seen as a negative association, the good understanding of HIV
485 transmission routes did help explain HBV transmission. In Burkina Faso, those diagnosed with HBV
486 outside of a hospital setting were often given poor information around HBV, similar to several of our
487 PLWHB who were diagnosed pre-travel.
488
489 An interesting finding in our study was that many PLWHB felt they were restricted in the evenings
490 due to taking medication, having to be home from work at a particular time or being unable to meet
491 friends. This has been described in HIV literature as people are more likely to take their medication at
492 home and do not want to carry tablets with them due to fear of discovery (31). It may also be that
493 the HBV clinic has given instructions around when to take medication related to food to reduce side
494 effects, and this is most convenient in the evenings. Education from the HBV clinic around the
495 flexibility of medication timing could be helpful, so PLWHB understand it can take be taken at any
496 time of day as long as this is consistent and does not need to interfere with any other social,
497 domestic or work commitments.

498 Several suggestions from participants here on how to improve care are already included in national
499 Kenyan guidelines on the management of HBV such as antenatal HBV testing and provision of
500 vaccination to close family contacts (32), however these are not universally incorporated into care. To
501 continue strengthening HBV care at KCRH and across the County, ensuring education is a funding
502 priority is crucial. Education was seen as one of the most important initiatives to increase diagnoses,
503 drive down stigma and improve HBV care pathways. As HCWs frequently transfer between facilities,
504 even localised educational initiatives have the potential to disseminate knowledge more broadly.
505

506 **Caveats and limitations**

507 We only included PLWHB in this study who were already linked to care and receiving treatment, and
508 both HCWs and PLWHB had been involved in previous research and have engaged with a peer
509 support group. These groups are likely to have better knowledge and PLWHB be more engaged in
510 care than those not involved in such a study. Here we included people from a limited geographical
511 area and only a small number of HCWs and PLHWB. To fully understand care barriers, we need to
512 undertake similar discussions with PLWHB who have been lost to follow up, those not offered
513 treatment and include community groups not tested or living with HBV; ideally a future study would
514 expand to include PLWHB and HCWs accessing healthcare services both in Kilifi and further afield.
515

516 **Conclusions**

517 Community education and decentralisation of care for PLWHB should be prioritised to reduce stigma,
518 enable easier access to care, reduce travel times and costs to reduce health inequities and support
519 wider roll-out of treatment. Community co-design is critical to ensure interventions are appropriate,
520 accessible, acceptable and affordable, and can be sustained over time.
521

522 **Acknowledgements**

We would like to thank all the PLWHB and HCWs who took part in these FGDs, along with the CCC team for facilitating the use of their clinic space to undertake this work. Without their enthusiasm and dedication to improving care for those living with HBV, this would not have been possible.

Data Availability

Full recordings and transcripts in both English and Kiswahili of these FGDs are held on a secure server at KWTRP but could be accessed by other studies on request to dgc@kemri-wellcome.org and approval by the data governance committee. For the purpose of Open Access, the author has applied a CC-BY public copyright license to any author accepted manuscript version arising from this submission. This manuscript was written with the permission of Director KEMRI CGMRC.

Conflicts of Interest

PCM has previously received funding from GSK for a PhD student in her group. This has had no influence over the planning or undertaking of the study, the writing of the manuscript or decision to publish.

References

1. Global hepatitis report 2024: action for access in low- and middle-income countries [Internet]. World Health Organization; 2024 [cited 2024 Jun 4]. Available from: https://www.who.int/publications/i/item/9789240091672

2. O'Hara GA, McNaughton AL, Maponga T, Jooste P, Ocama P, Chilengi R, et al. Hepatitis B virus infection as a neglected tropical disease. PLoS Negl Trop Dis [Internet]. 2017 Oct 5;11(10). Available from: http://dx.doi.org/10.1371/JOURNAL.PNTD.0005842

3. Delphin M, Mohammed KS, Downs LO, Lumley SF, Waddilove E, Okanda D, et al. Under-representation of the WHO African region in clinical trials of interventions against hepatitis B virus infection. Lancet Gastroenterol Hepatol. 2024 Feb 15;9(4):383–92.

4. Mugisha J, Mokaya J, Bukenya D, Ssembajja F, Mayambala D, Newton R, et al. A Study of Knowledge, Experience, and Beliefs About Hepatitis B Virus (HBV) Infection in South Western Uganda. Front Public Health. 2019 Oct 25;7:304.

5. Polaris Observatory Collaborators. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. Lancet Gastroenterol Hepatol. 2023 Oct;8(10):879–907.

6. Hepatitis Stigma Survey - World Hepatitis Alliance [Internet]. World Hepatitis Alliance - Fighting for a world free from viral hepatitis. World Hepatitis Alliance; 2023 [cited 2025 Jan 24]. Available from: https://www.worldhepatitisalliance.org/stigma/

7. Matthews PC, Jack K, Wang S, Abbott J, Bryce K, Cheng B, et al. A call for advocacy and patient voice to eliminate hepatitis B virus infection. Lancet Gastroenterol Hepatol. 2022 Apr;7(4):282–5.

8. Downs LO, Kabagambe K, Williams S, Waddilove E, Delphin M, Lumley SF, et al. Peer support for people living with hepatitis B virus-A foundation for treatment expansion. J Viral Hepat [Internet]. 2024 May 26; Available from: http://dx.doi.org/10.1111/jvh.13952

9. O'Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative research: a synthesis of recommendations. Acad Med. 2014 Sep;89(9):1245–51.

10. Tsofa B, O. L. , Ngala T, et al. ,, Kilifi county health sector review. *County Integrated Development Plan 2023-2027: Accelerating Socioeconomic Transfromation for Inclusive Growth*. 2023. [Internet]. Available from: https://kilifiassembly.go.ke/wp-content/uploads/2023/03/CIDP_III_Revised_Draft_1732023-Malindi_230329_162427.pdf

11. Kilifi County Data & Stats [Internet]. [cited 2025 Jan 10]. Available from: https://statskenya.co.ke/county-information/Kilifi/3

12. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection [Internet]. World Health Organization; 2024 [cited 2024 Apr 26]. Available from: https://www.who.int/publications/i/item/9789240090903

13. Downs LD, Matthews PM, Kagwanja NK. Focus group discussion guides used to facilitate discussions with people living with hepatitis B virus infection (PLWHB) and healthcare workers managing PLWHB in Kilifi, Kenya [Internet]. figshare; 2025 [cited 2025 Mar 3]. Available from: http://dx.doi.org/10.6084/m9.figshare.28350341.v1

14. Downs LO, Chirro O, Zaharani M, Safari B, Okanda D, Githinji G, et al. STRIKE-HBV: establishing an HBV screening programme in Kilifi, Kenya-challenges, successes and lessons learnt. Sex Transm Infect [Internet]. 2024 May 24; Available from: http://dx.doi.org/10.1136/sextrans-2024-056163

15. Downs L. Documents produced when setting up the STRIKE-HBV study including patient information leaflets and posters in English and Kiswahili [Internet]. figshare; 2024 [cited 2024 Nov 28]. Available from: http://dx.doi.org/10.6084/m9.figshare.25132256.v1

16. Home » Hepatitis B Foundation [Internet]. [cited 2025 Jan 21]. Available from: https://www.hepb.org/

17. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006 Jan 1;3(2):77–101.

18. Glaser BG, Strauss AL. The discovery of grounded theory: Strategies for qualitative research. 1st Edition. Routledge; 2017. 282 p.

592 19. Chen T, Borondy-Jenkins F, Zovich B, Block SJ, Moraras K, Chan A, et al. Existing knowledge,
593 myths, and perceptions about hepatitis B and liver cancer within highly impacted immigrant
594 communities. J Virus Erad. 2024 Jun 14;10(2):100379.

595 20. Wong RJ, Khalili M. A patient-centered hepatitis B virus (HBV) educational intervention
596 improves HBV care among underserved safety-net populations. J Clin Gastroenterol. 2020
597 Aug;54(7):642–7.

598 21. Jonas MC, Sheu Y-S, Wright K, Peyton L, Bishop RC, Basra S, et al. A care coordination program
599 to support patients with hepatitis B virus at Kaiser Permanente Mid-Atlantic States. BMC Health
600 Serv Res. 2024 Apr 18;24(1):482.

601 22. Lu J, Xu A, Wang J, Zhang L, Song L, Li R, et al. Direct economic burden of hepatitis B virus
602 related diseases: evidence from Shandong, China. BMC Health Serv Res. 2013 Jan 31;13(1):37.

603 23. Giles-Vernick T, Hejoaka F, Sanou A, Shimakawa Y, Bamba I, Traoré A. Barriers to Linkage to Care
604 for Hepatitis B Virus Infection: A Qualitative Analysis in Burkina Faso, West Africa. Am J Trop
605 Med Hyg. 2016 Dec 7;95(6):1368–75.

606 24. Adjei CA, Naab F, Donkor ES. Beyond the diagnosis: a qualitative exploration of the experiences
607 of persons with hepatitis B in the Accra Metropolis, Ghana. BMJ Open. 2017 Nov
608 3;7(11):e017665.

609 25. Jemutai J, Downs L, Anderson M, Cohen C, Seeley J, Sultan B, et al. Elimination of hepatitis B
610 requires recognition of catastrophic costs for patients and their families. Lancet Gastroenterol
611 Hepatol. 2025 Feb;10(2):100–3.

612 26. Adjei CA, Stutterheim SE, Naab F, Ruiter RAC. Chronic Hepatitis B stigma in Ghana: a qualitative
613 study with patients and providers. BMJ Open. 2019 Jun 27;9(6):e025503.

614 27. Freeland C, Farrell S, Kumar P, Kamischke M, Jackson M, Bodor S, et al. Common concerns,
615 barriers to care, and the lived experience of individuals with hepatitis B: a qualitative study.
616 BMC Public Health. 2021 May 28;21(1):1004.

617 28. Tang LY, Pene F, Cherfas L, Schwartz J, Baquero MC. Facilitators and barriers to accessing
618 hepatitis B care in the postpartum period among foreign-born New Yorkers: a qualitative
619 analysis of case notes. BMC Public Health. 2024 Jan 8;24(1):116.

620 29. Taheri Ezbarami Z, Hassani P, Zagheri Tafreshi M, Alavi Majd H. A qualitative study on individual
621 experiences of chronic hepatitis B patients. Nurs Open. 2017 Oct;4(4):310–8.

622 30. Mutyoba JN, Wandera C, Ejalu D, Seremba E, Beyagira R, Amandua J, et al. Feasibility and
623 acceptability of integrating hepatitis B care into routine HIV services: a qualitative study among
624 health care providers and patients in West Nile region, Uganda. BMC Health Serv Res. 2023 Jan
625 20;23(1):59.

626 31. Audi C, Jahanpour O, Antelman G, Guay L, Rutaihwa M, van de Ven R, et al. Facilitators and
627 barriers to antiretroviral therapy adherence among HIV-positive adolescents living in Tanzania.
628 BMC Public Health. 2021 Dec 13;21(1):2274.

629 32. Kenyan Ministry for Health. Kenyan Ministry for Health Guidelines Immunisation.pdf. 2023 Apr.

630